News | February 09, 2010

U.S. Insurers to Cover Radioembolization for Liver Cancer

February 9, 2010 - About 22,600 cases of primary liver cancer are diagnosed each year in the U.S. and one million annually worldwide, reports the American Cancer Society.

Two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, marking the largest favorable determinations for reimbursement coverage for this treatment by U.S. insurers.

The most common form of primary liver cancer is hepatocellular carcinoma (HCC), which in the U.S. is commonly caused by alcohol abuse or by the hepatitis B or hepatitis C virus. HCC is the fifth most common form of cancer in the world and is increasing globally due to an increase in the incidence of hepatitis. Treatment options for patients with primary liver cancer are limited as HCC is usually unresectable.

An important technique for treating radioembolization, also called selective internal radiation therapy (SIRT), is a process by which small beads or microspheres, containing the radioactive element yttrium-90, are delivered directly to the tumor using the tumor's own blood supply.

One form of radioembolization, TheraSphere by MDS Nordion, will now be reimbursed. TheraSphere is a low toxicity, liver cancer therapy that consists of millions of micro-glass beads containing radioactive yttrium-90. The product is injected by physicians into the main artery of the patient's liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood vessels. The TheraSphere treatment can generally be administered on an outpatient basis and does not usually require an overnight hospital stay. After treatment, most TheraSphere patients are eligible for further therapeutic options because the procedure preserves liver vascularity.

For more information: www.mdsnordion.com/therasphere

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Overlay Init